Preparing CJC-1295 with DAC for laboratory evaluation requires strict adherence to aseptic handling, precise solvent calculation, and low-shear dissolution protocols. This guide outlines standard laboratory reconstitution procedures, chemical stability profile, and analytical verification standards for researchers investigating this long-acting GHRH analog.
Preparing CJC-1295 with DAC for laboratory evaluation requires strict adherence to aseptic handling, precise solvent calculation, and low-shear dissolution protocols. This guide outlines standard laboratory reconstitution procedures, chemical stability profile, and analytical verification standards for researchers investigating this long-acting GHRH analog.
To mix CJC-1295 with DAC for laboratory research, sanitize the vial stoppers with 70% isopropyl alcohol, insert a sterile syringe containing bacteriostatic water (typically 1.0 to 2.0 mL), and gently direct the liquid stream down the glass wall of the vial. Allow the lyophilized powder to dissolve via passive diffusion or gentle rotation—never shake or vortex.
When preparing lyophilized peptides for in vitro or preclinical testing, utilizing high-grade bacteriostatic water containing 0.9% benzyl alcohol is essential. The benzyl alcohol acts as a bacteriostatic preservative, inhibiting microbial growth and allowing multiple sampling events from a single stock vial over an extended experimental period.
To ensure precise volumetric measurement, researchers should select sterile syringes with micro-fine graduations. Preserving vacuum pressure within the vial during solvent addition prevents liquid splatter and ensures complete dissolution of the lyophilized cake along the lower vessel walls.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid modified tetrasubstituted peptide analog of growth-hormone-releasing hormone (GHRH). The inclusion of the Drug Affinity Complex—specifically a reactive maleimidopropionic acid moiety attached to the C-terminus lysine residue—fundamentally Alters its pharmacokinetic profile relative to native GHRH(1-29).
Preclinical studies demonstrate that the DAC bioconjugate selectively and covalently binds to circulating endogenous serum albumin following administration in animal models. Because serum albumin has a extended half-life in circulation, this covalent coupling protects the CJC-1295 peptide chain from rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) and renal clearance.
As a specialized GHRH analog, CJC-1295 with DAC binds to the pituitary GHRH receptor to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH). In laboratory research, it is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research without requiring frequent repeated administration.
In animal models, CJC-1295 with DAC exhibits an extended half-life of approximately 6 to 8 days, maintaining elevated baseline plasma GH and IGF-1 concentrations far longer than non-conjugated GHRH fragments. This extended signaling duration makes it a useful reference compound in longitudinal studies evaluating systemic metabolic alterations and cellular regeneration.
Investigators utilize CJC-1295 with DAC in models of tissue repair research, focusing on extracellular matrix remodeling, collagen deposition, and skeletal muscle satellite cell activation. Preclinical data indicate that continuous GHRH receptor stimulation supports downstream anabolic cascades mediated by systemic IGF-1 upregulation.
Furthermore, researchers exploring research peptides for metabolic investigation examine how sustained GHRH signaling influences nitrogen retention, lipid oxidation rates, and soft tissue repair pathways in rodent models of injury or age-related metabolic decline.
Determining the target concentration of CJC-1295 with DAC stock solution requires matching the mass of the lyophilized peptide cake to the precise volume of reconstitution diluent added. Laboratory calculations should always account for total mass (expressed in milligrams or micrograms) versus fluid volume (expressed in milliliters).
For example, adding 2.0 mL of bacteriostatic water to a vial containing 2.0 mg (2,000 mcg) of CJC-1295 with DAC yields a final working concentration of 1.0 mg/mL (100 mcg per 0.1 mL). Alternatively, reconstituting a 5.0 mg vial with 2.5 mL of solvent produces a 2.0 mg/mL stock solution.
Maintaining consistent concentration standards across experimental groups is crucial for reproducibility. Researchers should record the reconstitution volume, batch number, and calculated concentration on the laboratory log sheet immediately following preparation.
When designing preclinical protocols to evaluate growth hormone secretagogues, choosing the correct GHRH peptide variant depends on whether the study demands continuous baseline elevation or transient pulsatile spikes.
Unlike CJC-1295 No DAC (also known as Modified GRF 1-29), which lacks the albumin-binding linker and possesses a brief biological half-life of 30 minutes, the DAC-conjugated variant maintains active GHRH receptor activation for several days. In contrast, short-acting analogs like Sermorelin and targeted pituitary stimulators like Tesamorelin trigger rapid, acute GH release followed by quick clearance.
A comprehensive review of GHRH secretagogues highlights these structural differences: while native GHRH fragments require frequent dosing paradigms in animal models to mimic natural pulsatility, CJC-1295 with DAC provides a continuous baseline stimulus ideal for testing long-term tissue repair and metabolic parameter shifts. Comparative details can be further explored in our analytical resource on CJC-1295 DAC vs. No DAC.
Lyophilized peptide cakes are structurally delicate assemblies of secondary and tertiary protein folding patterns. Improper solvent addition can lead to mechanical shear stress, causing physical aggregation or partial degradation of the peptide sequence.
During reconstitution, the diluent stream should be aimed against the glass inner wall of the vial rather than directly onto the dried cake. The solvent should be permitted to submerge the material slowly. Gentle, horizontal rotation of the vial facilitates dissolution without entraining air bubbles.
Vortex mixing, vigorous shaking, or rapid mechanical agitation must be strictly avoided. If small undissolved particulates remain, allow the vial to stand at 2°C to 8°C for 10–15 minutes until complete clarification is achieved before sampling for assays.
Lyophilized CJC-1295 with DAC remains stable when stored in sub-zero temperatures (-20°C to -80°C), protected from light exposure and atmospheric moisture. Under these conditions, the peptide cake maintains chemical integrity for extended periods prior to reconstitution.
Once dissolved in bacteriostatic water, the peptide is susceptible to hydrolysis, oxidation, and photolytic degradation over time. Reconstituted stock solutions must be stored under refrigeration between 2°C and 8°C and used within 28 days to prevent loss of potency and degradation of the maleimide functional group.
Avoid repeated freeze-thaw cycles for reconstituted solution. Freezing liquid aliquots can cause ice crystal growth that disrupts the peptide backbone and compromises the reactivity of the DAC linker.
Reliable preclinical research requires verified high-purity reagents. Impurities such as truncated peptide fragments, residual coupling reagents, or endotoxins can alter cellular response profiles and obscure assay conclusions.
PX1 Research ensures quality control by subjecting every production lot of CJC-1295 with DAC to dual analytical verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). These tests confirm both chemical purity (exceeding 99%) and exact molecular weight matching theoretical values.
Furthermore, total endotoxin testing using Limulus Amebocyte Lysate (LAL) assays guarantees that bacterial endotoxin levels remain below strict laboratory limits (<0.05 EU/mg), preventing non-specific inflammatory responses in cell culture or animal models. Every order includes a lot-specific Certificate of Analysis (COA) generated in an ISO 17025 accredited laboratory facility.
For academic, biotechnology, and institutional researchers requiring compliant reagents, sourcing from verified American manufacturers is critical for experimental consistency. Low-grade suppliers often yield inconsistent batch-to-batch purity or inaccurate mass fill quantities.
PX1 Research synthesizes all compounds in domestic, GMP-compliant facilities adhering to rigid ISO standards. Institutional buyers seeking bulk reagents for large-scale preclinical studies can explore our dedicated wholesale lab accounts for streamlined supply logistics.
All materials ship directly from our state-of-the-art logistics hubs in California and Arizona. Orders placed Monday through Friday before cut-off times qualify for same-day dispatch, ensuring optimal temperature control and minimal transit delays. Explore our comprehensive research hub to access detailed technical documentation and full compound specifications.
What volume of bacteriostatic water is standard for mixing CJC-1295 with DAC?
Common laboratory protocols utilize 1.0 mL to 2.0 mL of bacteriostatic water per vial, depending on the desired target concentration for volumetric sampling in preclinical assays.
Why is bacteriostatic water preferred over sterile water for injection?
Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial proliferation. This allows researchers to draw multiple aliquots from the same reconstituted stock vial over several days, whereas sterile water lacks preservatives and must be used immediately.
How should reconstituted CJC-1295 with DAC be stored in the lab?
Reconstituted CJC-1295 with DAC solutions must be stored under refrigeration at 2°C to 8°C, protected from light, and used within 28 days to maintain chemical stability and functional integrity.
What is the primary difference between CJC-1295 with DAC and CJC-1295 No DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that covalently binds to serum albumin, extending its biological half-life to 6–8 days. CJC-1295 No DAC lacks this complex and exhibits a half-life of approximately 30 minutes.
Can CJC-1295 with DAC be vortexed to speed up dissolution?
No. Mechanical shear stress from vortexing or vigorous shaking can denature the peptide structure and induce aggregation. Dissolution should occur passively or via gentle rotational swirling.
What analytical tests verify the purity of PX1 Research peptides?
PX1 Research verifies compounds using RP-HPLC for purity (>99%), Mass Spectrometry (MS) for molecular weight confirmation, and LAL assays for bacterial endotoxin detection.
What is the receptor target of CJC-1295 with DAC?
CJC-1295 with DAC acts as a selective agonist at the growth-hormone-releasing hormone receptor (GHRHR) located on pituitary somatotropes.
Does PX1 Research provide lot-specific Certificates of Analysis?
Yes, every batch of CJC-1295 with DAC includes a lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited testing facility.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.